면역치료제 시장 규모, 점유율, 성장, 세계 산업 분석, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of immunotherapy drugs Market

The global immunotherapy drugs market size was valued at USD 343.98 billion in 2025 and is projected to grow from USD 394.36 billion in 2026 to USD 1,220.02 billion by 2034, exhibiting a CAGR of 15.16% during the forecast period. North America dominated the global market with a 47.54% share in 2025, supported by high healthcare spending, extensive clinical trial activity, advanced oncology research, and a growing number of approved immunotherapy products.

Immunotherapy drugs are medications designed to stimulate, enhance, or restore the immune system's ability to recognize and destroy disease-causing cells. The market is expanding due to the rising incidence of cancer, advances in oncology research, increasing regulatory approvals for novel therapies, and growing healthcare expenditure. Pharmaceutical and biopharmaceutical companies are also increasingly developing combination regimens that pair immunotherapies with targeted therapies.

Market Definition and Scope

The immunotherapy drugs market includes therapies such as monoclonal antibodies, CAR-T cell therapies, cancer vaccines, and other immune-based treatments used across oncology, autoimmune diseases, infectious diseases, and other indications. The market also covers intravenous and subcutaneous administration routes and distribution through hospital pharmacies, retail pharmacies and drug stores, and online pharmacies.

Market Dynamics

Driver - Rapid Growth in Cell Therapies: The expansion of CAR-T therapies and emerging allogeneic "off-the-shelf" platforms is supporting market growth. Increasing clinical success in hematological malignancies, investments in cell-therapy manufacturing, gene-editing technologies, and supportive regulatory pathways are strengthening the segment. In June 2025, Allogene Therapeutics reported positive Phase 1 results for its CD70-targeting products.

Restraint - High Treatment Costs: High costs associated with advanced immunotherapies restrict patient access, particularly in low- and middle-income countries. Expensive drug development, strict regulatory requirements, and inadequate reimbursement practices further limit market expansion.

Opportunity - Immunotherapy-Targeted Therapy Combinations: Combination therapies are creating significant opportunities by improving treatment responses and addressing resistance mechanisms across hematologic and solid cancers. Increasing approvals in first-line settings are also expanding the potential patient population.

Challenge - Safety Concerns: Severe immune-related adverse events, including cytokine release syndrome, neurotoxicity, autoimmune reactions, myocarditis, and severe colitis, remain important challenges. Safety concerns can also complicate clinical development and regulatory review.

Trend - Increasing Approvals for Solid Tumors: Growing approvals of checkpoint inhibitors, bispecific antibodies, and cell-based immunotherapies for solid tumors are expanding the addressable market. Therapies are increasingly moving into earlier treatment lines for cancers such as lung, breast, gastrointestinal, cervical, and melanoma.

Segmentation Analysis

By Type: Monoclonal antibodies held the largest market share in 2025 due to increasing investment, expanding clinical pipelines, product launches, and regulatory approvals. CAR-T cell therapies are projected to be the fastest-growing segment, with a 34.08% CAGR.

By Indication: Oncology dominated the market in 2025 and is anticipated to account for 87.2% in 2026, driven by the global cancer burden and strong clinical adoption. Autoimmune diseases are projected to grow at a 13.02% CAGR.

By Route of Administration: Intravenous administration led the market and is expected to hold an 85.4% share in 2026, while subcutaneous administration is projected to grow at a 19.54% CAGR.

By Distribution Channel: Hospital pharmacies dominated and are expected to maintain an 80.1% share in 2026, while online pharmacies are projected to grow at a 21.10% CAGR.

Regional Insights

North America: The region generated USD 163.52 billion in 2025 and remained the leading market. The U.S. market is projected to reach USD 171.04 billion in 2026, supported by healthcare investment, clinical research, and product approvals.

Europe: Europe is projected to reach USD 89.10 billion in 2026, recording a 14.46% growth rate. The U.K., Germany, and France are expected to generate USD 18.24 billion, USD 19.92 billion, and USD 14.32 billion, respectively.

Asia Pacific: The regional market is projected to reach USD 71.30 billion in 2026, supported by rising cancer incidence, clinical development, and improved access to innovative therapies. China and India are projected to reach USD 21.43 billion and USD 12.69 billion.

Latin America and Middle East & Africa: Latin America is expected to reach USD 26.57 billion in 2026, while the GCC market is projected to reach USD 7.42 billion, supported by increasing clinical research and commercial access.

Competitive Landscape

The market has a semi-consolidated competitive structure. Major players include Merck & Co., Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd, AstraZeneca, Pfizer Inc., Novartis AG, Gilead Sciences, Inc., Johnson & Johnson, Amgen Inc., and Regeneron Pharmaceuticals, Inc. Companies are strengthening their positions through clinical innovation, collaborations, biologics manufacturing, product development, and strategic investments.

Report Coverage

The report provides comprehensive analysis of market size and forecast for 2025, 2026, and 2034, along with market dynamics, trends, segmentation, regional insights, technological advancements, pipeline analysis, product development, strategic initiatives, competitive landscape, and key industry developments.

Conclusion

The global immunotherapy drugs market is projected to expand from USD 343.98 billion in 2025 to USD 394.36 billion in 2026 and USD 1,220.02 billion by 2034. Rising cancer incidence, advances in cell therapies, increasing regulatory approvals, and growing adoption of immunotherapy-targeted combinations will continue to support market expansion. At the same time, high treatment costs and safety concerns remain important considerations. Continued innovation in monoclonal antibodies, CAR-T therapies, solid-tumor applications, and subcutaneous formulations is expected to shape the market's future development.

Global Immunotherapy Drugs Market Scope

By Type

• Monoclonal Antibodies (mAbs)
• CAR-T Cell Therapies
• Cancer Vaccines
• Others

By Indication

• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Others

By Route of Administration

• Intravenous
• Subcutaneous

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies & Drug Stores
• Online Pharmacies

By Region

• North America (By Type, Indication, Route of Administration, Distribution Channel, and Country)
  • U.S.
  • Canada
• Europe (By Type, Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Germany
  • U.K.
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
• Asia Pacific (By Type, Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
  • China
  • Japan
  • India
  • Australia
  • Southeast Asia
  • Rest of Asia Pacific
• Latin America (By Type, Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Type, Indication, Route of Administration, Distribution Channel, and Country/Sub-region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Prevalence of Key Diseases, By Key Countries/Regions
• 4.2. Regulatory Scenario, By Key Countries/Region
• 4.3. Pipeline Analysis, By Key Players
• 4.4. Technological Advancements in Immunotherapy Drugs
• 4.5. Key Industry Developments - Mergers, Acquisitions, Partnerships etc.
• 4.6. New Product Launches, By Key Players

5. Global Immunotherapy Drugs Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Type
  • 5.1.1. Immune checkpoint inhibitor
  • 5.1.2. Monoclonal Antibodies (mAbs)
  • 5.1.3. CAR-T Cell Therapies
  • 5.1.4. Cancer Vaccines
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Indication
  • 5.2.1. Oncology
  • 5.2.2. Autoimmune Diseases
  • 5.2.3. Infectious Diseases
  • 5.2.4. Others
• 5.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 5.3.1. Intravenous
  • 5.3.2. Subcutaneous
• 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 5.4.1. Hospital Pharmacies
  • 5.4.2. Retail Pharmacies & Drug Stores
  • 5.4.3. Online Pharmacies
• 5.5. Market Analysis, Insights and Forecast - Region
  • 5.5.1. North America
  • 5.5.2. Europe
  • 5.5.3. Asia Pacific
  • 5.5.4. Latin America
  • 5.5.5. Middle East & Africa

6. North America Immunotherapy Drugs Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Type
  • 6.1.1. Immune checkpoint inhibitor
  • 6.1.2. Monoclonal Antibodies (mAbs)
  • 6.1.3. CAR-T Cell Therapies
  • 6.1.4. Cancer Vaccines
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Indication
  • 6.2.1. Oncology
  • 6.2.2. Autoimmune Diseases
  • 6.2.3. Infectious Diseases
  • 6.2.4. Others
• 6.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 6.3.1. Intravenous
  • 6.3.2. Subcutaneous
• 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 6.4.1. Hospital Pharmacies
  • 6.4.2. Retail Pharmacies & Drug Stores
  • 6.4.3. Online Pharmacies
• 6.5. Market Analysis, Insights and Forecast - By Country
  • 6.5.1. U.S.
  • 6.5.2. Canada

7. Europe Immunotherapy Drugs Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Type
  • 7.1.1. Immune checkpoint inhibitor
  • 7.1.2. Monoclonal Antibodies (mAbs)
  • 7.1.3. CAR-T Cell Therapies
  • 7.1.4. Cancer Vaccines
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Indication
  • 7.2.1. Oncology
  • 7.2.2. Autoimmune Diseases
  • 7.2.3. Infectious Diseases
  • 7.2.4. Others
• 7.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 7.3.1. Intravenous
  • 7.3.2. Subcutaneous
• 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 7.4.1. Hospital Pharmacies
  • 7.4.2. Retail Pharmacies & Drug Stores
  • 7.4.3. Online Pharmacies
• 7.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.5.1. U.K.
  • 7.5.2. Germany
  • 7.5.3. France
  • 7.5.4. Italy
  • 7.5.5. Spain
  • 7.5.6. Scandinavia
  • 7.5.7. Rest of Europe

8. Asia Pacific Immunotherapy Drugs Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Type
  • 8.1.1. Immune checkpoint inhibitor
  • 8.1.2. Monoclonal Antibodies (mAbs)
  • 8.1.3. CAR-T Cell Therapies
  • 8.1.4. Cancer Vaccines
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Indication
  • 8.2.1. Oncology
  • 8.2.2. Autoimmune Diseases
  • 8.2.3. Infectious Diseases
  • 8.2.4. Others
• 8.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 8.3.1. Intravenous
  • 8.3.2. Subcutaneous
• 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 8.4.1. Hospital Pharmacies
  • 8.4.2. Retail Pharmacies & Drug Stores
  • 8.4.3. Online Pharmacies
• 8.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.5.1. China
  • 8.5.2. Japan
  • 8.5.3. India
  • 8.5.4. Australia
  • 8.5.5. Southeast Asia
  • 8.5.6. Rest of Asia Pacific

9. Latin America Immunotherapy Drugs Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Type
  • 9.1.1. Immune checkpoint inhibitor
  • 9.1.2. Monoclonal Antibodies (mAbs)
  • 9.1.3. CAR-T Cell Therapies
  • 9.1.4. Cancer Vaccines
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Indication
  • 9.2.1. Oncology
  • 9.2.2. Autoimmune Diseases
  • 9.2.3. Infectious Diseases
  • 9.2.4. Others
• 9.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 9.3.1. Intravenous
  • 9.3.2. Subcutaneous
• 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 9.4.1. Hospital Pharmacies
  • 9.4.2. Retail Pharmacies & Drug Stores
  • 9.4.3. Online Pharmacies
• 9.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.5.1. Brazil
  • 9.5.2. Mexico
  • 9.5.3. Rest of Latin America

10. Middle East & Africa Immunotherapy Drugs Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Type
  • 10.1.1. Immune checkpoint inhibitor
  • 10.1.2. Monoclonal Antibodies (mAbs)
  • 10.1.3. CAR-T Cell Therapies
  • 10.1.4. Cancer Vaccines
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Indication
  • 10.2.1. Oncology
  • 10.2.2. Autoimmune Diseases
  • 10.2.3. Infectious Diseases
  • 10.2.4. Others
• 10.3. Market Analysis, Insights and Forecast - By Route of Administration
  • 10.3.1. Intravenous
  • 10.3.2. Subcutaneous
• 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
  • 10.4.1. Hospital Pharmacies
  • 10.4.2. Retail Pharmacies & Drug Stores
  • 10.4.3. Online Pharmacies
• 10.5. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.5.1. GCC
  • 10.5.2. South Africa
  • 10.5.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Merck & Co.
  • 11.2.2. Bristol-Myers Squibb Company
  • 11.2.3. F. Hoffmann-La Roche Ltd
  • 11.2.4. AstraZeneca
  • 11.2.5. Pfizer Inc.
  • 11.2.6. Novartis AG
  • 11.2.7. Gilead Sciences, Inc.
  • 11.2.8. Johnson & Johnson
  • 11.2.9. Amgen Inc.
  • 11.2.10. Regeneron Pharmaceuticals, Inc.